4/A//SEC Filing
Eiger BioPharmaceuticals, Inc. 4/A
Accession 0001209191-16-141538
CIK 0001305253operating
Filed
Sep 14, 8:00 PM ET
Accepted
Sep 15, 2:36 PM ET
Size
9.1 KB
Accession
0001209191-16-141538
Insider Transaction Report
Form 4/AAmended
Cory David A
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2016-03-23+285,991→ 285,991 totalExercise: $15.89Exp: 2026-03-23→ Common Stock (285,991 underlying)
Footnotes (2)
- [F1]The option will vest as to 25% of the option shares on March 23, 2017 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.
- [F2]The option grant was approved by Issuer's board of directors on March 22, 2016, subject to stockholder approval of an amendment to the Issuer's 2013 Equity Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016.
Documents
Issuer
Eiger BioPharmaceuticals, Inc.
CIK 0001305253
Entity typeoperating
Related Parties
1- filerCIK 0001305253
Filing Metadata
- Form type
- 4/A
- Filed
- Sep 14, 8:00 PM ET
- Accepted
- Sep 15, 2:36 PM ET
- Size
- 9.1 KB